A Agilent Technologies Inc.

Agilent Announces New, Innovative 7850 ICP-MS System

(NYSE: A) today announced a new ICP-MS instrument, the , that provides new smart tools to minimize common time traps that can affect ICP-MS analysis workflows.

Building on decades of innovation, the 7850 ICP-MS combines market-leading performance with new smart software features that bring advanced capabilities to the routine ICP-MS laboratory. The new 7850 provides solutions that enable customers to be more productive and efficient while ensuring high quality results.

“The biggest impact of this new system will be in helping our customers avoid common time traps that can result in wasted time, higher costs, lower productivity, and ultimately staff stress and potential turnover,” said Keith Bratchford, vice president, and general manager, Agilent Spectroscopy. “The smart tools and streamlined workflows of the 7850 simplify ICP-MS analysis, assisting customers in each step of their typical sample analysis.”

“These smart features are particularly helpful for less experienced users who are often tasked with operating the ICP-MS in small- to medium-sized contract testing labs,” Bratchford added.

The costs to a lab that fails to recognize or address common time traps are not just limited to lost time and revenue. Unnecessary method setup steps, instrument checks, manual data reviews, and the need for sample reanalysis also place more pressure on busy lab staff. This workload can impact sample turnaround time and the quality of the results that customers expect—putting a laboratory’s reputation at risk.

The 7850 uses a configuration that is optimized to handle the range of sample types measured in typical ICP-MS applications while ensuring data is free from common sources of error. Smart tools help customers through the initial setup of the instrument and required methods, and guides users through the typical ICP-MS workflow that is used to measure sample batches. Smart functions also assist with data review, eliminating the need for an ICP-MS expert to perform the important step of verifying data quality.

The new 7850 is the smart way to ensure fast setup and streamlined analysis for great results in typical ICP-MS applications.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on , , and .

EN
02/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch